Tag Archives: Dr. Ed Wirth

Patients with Complete Paralysis Show Additional Recovery of Arm, Hand and Finger Function at 9-months After Treatment with Asterias’ AST-OPC1

Third patient recovers two motor levels; three of six (50%) patients in AIS-A 10 million cell cohort have now recovered two motor levels on at least one side FREMONT, Calif., June 13, 2017 /PRNewswire/ –Asterias Biotherapeutics, Inc. (NYSE MKT: AST), … Continue reading

Posted in Chronic Spinal Cord Injury Research, Regenerative Medicine, spinal cord injury research, Stem Cell Research | Tagged , , | 2 Comments

Early Phase Clinical Trials of Human Embryonic Stem Cell-Derived Oligodendrocyte Progenitor Cells (AST-OPC1) in Patients with Subacute SCI

Extensive preclinical testing of AST-OPC1 (formerly GRNOPC1) in animal models of traumatic SCI demonstrated that these cells survive, migrate throughout the injury site, and improve locomotor function. Therefore, a phase 1 clinical trial was initiated to assess the safety of … Continue reading

Posted in Regenerative Medicine, spinal cord injury research, Stem Cell Research | Tagged ,

Cell-Based Therapies for SCI: Lessons Learned in Planning and Conducting Two Phase 1 Safety Trials Over the Past 18 Years

Ed Wirth, MD, PhD Spinal Cord Injury Clinical Scientist  

Posted in Chronic Spinal Cord Injury Research, Regenerative Medicine, spinal cord injury research, Stem Cell Research | Tagged , , , , , , , , , ,